Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Department of Radiology, Hainan Province People's Hospital, Haikou, China.
Cancer Res Treat. 2018 Jul;50(3):777-790. doi: 10.4143/crt.2017.255. Epub 2017 Jul 24.
The purpose of this study was to investigate the effect of neutropenia during the first cycle of induction chemotherapy (IC-1) on survival in locoregionally advanced nasopharyngeal carcinoma (LANPC).
Eligible patients (n=545) with LANPC receiving IC+concurrent chemoradiotherapy were included. Based on nadir neutrophil afterIC-1, all patientswere categorized into three groups: no/grade 1-2/grade 3-4 neutropenia. Five-year overall survival (OS) and disease-free survival (DFS) were compared between groups and subgroups stratified by IC regimen. We also explored the occurrence of IC-1-induced myelosuppression events and the minimal value of post-treatment neutrophil-to-lymphocyte ratio (post-NLRmin). Univariate/multivariate analyses were performed to investigate the effect of IC-1-induced neutropenia, timing of neutropenia, number of myelosuppression events, and high post-NLRmin on OS/DFS.
Grade 1-2/grade 3-4 neutropeniawere associatedwith poorer OS/DFS than no neutropenia (all p < 0.05); OS/DFS were not significantly different between patients experiencing grade 1-2 vs. 3-4 neutropenia. Neutropenia had no significant effect on OS/DFS in patients receiving docetaxel-cisplatin-5-fluorouracil (TPF). Grade 1-2 (grade 3-4) neutropenia negatively influenced OS/DFS in patients receiving cisplatin-5-fluorouracil (PF) (PF and docetaxel-cisplatin [TP]; all p < 0.05). Neutropenia, two/three myelosuppression events, and high post-NLRmin (≥ 1.33) was most frequent on days 5-10, second and third week of IC-1, respectively. After adjustment for covariates, IC-1-induced neutropenia, two/three myelosuppression events, and post-NLRmin ≥ 1.33were validated as negative predictors of OS/DFS (all p < 0.05); timing of neutropenia had no significant effect.
Occurrence of neutropenia, number of myelosuppression events, and high post-NLRmin during PF/TP IC-1 have prognostic value for poor survival in LANPC.
本研究旨在探讨诱导化疗(IC-1)期间中性粒细胞减少对局部晚期鼻咽癌(LANPC)患者生存的影响。
本研究纳入了接受 IC+同期放化疗的 LANPC 患者(n=545)。根据 IC-1 后中性粒细胞最低点,所有患者被分为三组:无/1-2 级/3-4 级中性粒细胞减少症。比较各组之间以及按 IC 方案分层的亚组之间的 5 年总生存率(OS)和无病生存率(DFS)。我们还探讨了 IC-1 诱导的骨髓抑制事件的发生情况和治疗后中性粒细胞与淋巴细胞比值(post-NLRmin)的最小值。采用单因素/多因素分析探讨 IC-1 诱导的中性粒细胞减少症、中性粒细胞减少症发生时间、骨髓抑制事件次数和 post-NLRmin 高值对 OS/DFS 的影响。
1-2 级/3-4 级中性粒细胞减少症与无中性粒细胞减少症相比,OS/DFS 更差(均 p < 0.05);1-2 级中性粒细胞减少症与 3-4 级中性粒细胞减少症患者的 OS/DFS 无显著差异。在接受多西他赛-顺铂-5-氟尿嘧啶(TPF)治疗的患者中,中性粒细胞减少症对 OS/DFS 无显著影响。1-2 级(3-4 级)中性粒细胞减少症对接受顺铂-5-氟尿嘧啶(PF)治疗的患者的 OS/DFS 有负面影响(PF 和多西他赛-顺铂[TP];均 p < 0.05)。IC-1 第 5-10 天、第 2 周和第 3 周最常发生中性粒细胞减少症、两次/三次骨髓抑制事件和 post-NLRmin(≥1.33)。在调整协变量后,IC-1 诱导的中性粒细胞减少症、两次/三次骨髓抑制事件和 post-NLRmin≥1.33 被验证为 OS/DFS 的负预测因子(均 p < 0.05);中性粒细胞减少症发生时间无显著影响。
PF/TP IC-1 期间中性粒细胞减少症、骨髓抑制事件次数和 post-NLRmin 高值与 LANPC 患者生存不良相关。